858 related articles for article (PubMed ID: 17960951)
1. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
Fleurence RL; Iglesias CP; Johnson JM
Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
4. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.
Kreck S; Klaus J; Leidl R; von Tirpitz C; Konnopka A; Matschinger H; König HH
Pharmacoeconomics; 2008; 26(4):311-28. PubMed ID: 18370566
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
8. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Hiligsmann M; Reginster JY
Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
12. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
13. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
14. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
15. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
16. Vitamin K to prevent fractures in older women: systematic review and economic evaluation.
Stevenson M; Lloyd-Jones M; Papaioannou D
Health Technol Assess; 2009 Sep; 13(45):iii-xi, 1-134. PubMed ID: 19818211
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.
Jansen JP; Gaugris S; Bergman G; Sen SS
Curr Med Res Opin; 2008 Mar; 24(3):671-84. PubMed ID: 18221588
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
Yoshizawa T; Nishino T; Okubo I; Yamazaki M
Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks.
van Staa TP; Kanis JA; Geusens P; Boonen A; Leufkens HG; Cooper C
Value Health; 2007; 10(5):348-57. PubMed ID: 17888099
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
